ClinicalTrialsFinder
RecruitingPhase 2NCT06255223

A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy

An Open-label, Single-arm Study to Evaluate the Efficacy and Safety of Multimodal Radiotherapy in the Treatment of Renal Cell Carcinoma Progressed After Prior Immunotherapy

Sponsor

Jinling Hospital, China

Enrollment

35 participants

Start Date

Dec 15, 2023

Study Type

INTERVENTIONAL

Conditions

Renal Cell CarcinomaRadiotherapyImmune Checkpoint Inhibitor

Summary

The objective of this single-center clinical study was to evaluate the disease control rate(DCR) and safety of multimodal radiotherapy in the treatment of patients with renal cell carcinoma (RCC) progressed after prior immunotherapy.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study tests multimodal radiotherapy (a combination of different radiation approaches) alongside immunotherapy for people with metastatic kidney cancer (renal cell carcinoma) whose prior treatments have stopped working. Combining radiation with immune checkpoint drugs may boost the immune system's ability to fight cancer beyond the areas being irradiated. **You may be eligible if...** - You have confirmed metastatic or unresectable kidney cancer - You have progressed on 1–2 prior treatments, including at least one immune checkpoint inhibitor - You have at least two measurable metastases at different locations - You can tolerate radiation therapy alongside ongoing immunotherapy **You may NOT be eligible if...** - You have not tried prior systemic therapies - You have only one metastatic site - Your overall health is too poor to tolerate treatment - You have conditions making radiation or immunotherapy unsafe Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONHigh-dose Radiotherapy (HDRT)

SBRT was adopted, and radiotherapy plan was made according to the location and size of lesions (total dose 20-70Gy, 5-12Gy every time).

RADIATIONLow-dose Radiotherapy (LDRT)

Radiotherapy plan was made according to the location and size of lesions (total dose 2Gy, 1Gy every time). After completing SBRT, LDRT was performed on as many metastatic sites as possible.

DRUGAnti-PD-1 monoclonal antibody

At the end of multimodal radiotherapy, immunotherapy was given within 7 days and in a subsequent LDRT. The maximum duration is 24 months.

Locations(1)

Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University

Nanjing, Jiangsu, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06255223

Related Trials

A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

NCT07227402111 locations

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

NCT0711504313 locations

Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC

NCT076466391 location

A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

NCT071956829 locations

Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma

NCT076448972 locations